semaglutide oral approval FDA Approves GLP-1 Pill for Primary, Secondary Cardiovascular Protection Helpful guidance for the newly

The empagliflozinlinagliptin combination sits at an important intersection of: simplicity safety adherence cardiorenal protection metabolic improvement particularly in real-world clinical practice where affordability and long-term adherence strongly influence outcomes

But we have two excellent guests, WIRED senior writer Kate Knibbs

Discuss your goals and expectations openly with your provider

Semaglut is not recommended for use in patients with end-stage renal disease

BPC-157 and the Difference Between an Evidence Gap and a Cover-Up: What the entire human evidence base actually looks like, and the questions to ask next